Search results for "quinoline"
showing 10 items of 391 documents
CCDC 262065: Experimental Crystal Structure Determination
2006
Related Article: G.Stajer, A.E.Szabo, G.Turos, P.Sohar, R.Sillanpaa|2005|Eur.J.Org.Chem.|2005|4154|doi:10.1002/ejoc.200500155
CCDC 633848: Experimental Crystal Structure Determination
2007
Related Article: M.Albrecht, Triyanti, S.Schiffers, O.Osetska, G.Raabe, T.Wieland, L.Russo, K.Rissanen|2007|Eur.J.Org.Chem.|2007|2850|doi:10.1002/ejoc.200700130
Synthesis and characterization of sulfonamides containing 8-aminoquinoline and their Ni(II) complexes. Crystalline structures of the Ni complexes
2002
Reaction between 8-aminoquinoline and benzenesulfonyl, toluene-4-sulfonyl and naphthalene-2-sulfonyl chlorides in a basic medium leads to the formation of the corresponding sulfonamides. Reaction of these sulfonamides with Ni(II) salts leads to the formation of the corresponding complexes, with a NiL 2 stoichiometry. Determination of the crystalline structure by X-ray diffraction shows an octahedral environment for the Ni(II) ions, sulfonamides acting as bidentate ligands and two solvent molecules completing the octahedral coordination. The spectroscopic and magnetic properties of these compounds are also discussed.
Azido and thiocyanato bridged dinuclear Ni(II) complexes involving 8-aminoquinoline based Schiff base as blocking ligands: Crystal structures, ferrom…
2020
Abstract The use of two 8-aminoquinoline-based tridentate N3-donor rigid Schiff base ligands (L1 and L2) with Ni(II) in the presence of the pseudohalides, NaN3 and NaSCN results in the crystallization of the two novel Ni(II) dimers: [Ni2(L1)2(µ1,1′-N3)2(N3)2] (1) and [Ni2(L2)2(µ1,3-NCS)2(NCS)2] (2). Both complexes are centrosymmetric Ni(II) dimers where the Schiff base ligands coordinate the octahedral Ni(II) centres in a mer configuration with one terminal and two bridging pseudohalide ligands in the remaining positions. Complex 1 shows Ni(II) ions connected by a double µ1,1′-N3− bridge whereas in complex 2 the Ni(II) ions are connected by a double µ1,3-NCS− bridge. The magnetic properties…
Perspectives for the Treatment of Brucellosis in the 21st Century: The Ioannina Recommendations
2007
Policy Forum. Competing interests: ER has received research grants from Daiichi, Bayer, and Theravance and has served as a consultant to Pfizer, Theravance, Bayer, Wyeth, Rosetta, and BiondVax. Summary Points Brucellosis remains the commonest anthropozoonosis worldwide, and its treatment remains complex, requiring protracted administration of more than one antibiotic. In November 2006, a consensus meeting aimed at reaching a common specialist statement on the treatment of brucellosis was held in Ioannina, Greece under the auspices of the International Society of Chemotherapy and the Institute of Continuing Medical Education of Ioannina. The author panel suggests that the optimal treatment o…
N-SUBSTITUTION AND á1-ADRENERGIC RECEPTOR AFFINITY OF LAUDANOSINE ANALOGUES
2006
Benzyltetrahydroisoquinoline (BTHIQ) molecules are able to adopt widely differing conformations that depend on the presence or absence of N-substituents. To assess the possible role of BTHIQ conformation on the affinity of these compounds for α 1 -adrenergic receptors, of interest for the management of hypertension, the racemic N-unsubstituted BTHIQ norlaudanosine and a series of N-alkylated derivatives were assessed for binding to rat brain cortical sites labelled with the radioligand [3H]prazosin. The α 1 -adrenergic affinity in this series increased with the bulk of the substituent on the nitrogen atom, from the N-ethyl to the N-propyl analogue. Comparison of these results with published…
Synthetic antioxidants: biochemical actions and interference with radiation, toxic compounds, chemical mutagens and chemical carcinogens.
1984
Abstract Biological actions of 4 commonly used synthetic antioxidants — butylated hydroxyanisole, butylated hydroxytoluene, ethoxquin and propul gallate — on the molecular, cellular and organ level are compiled. Such actions may be divided into modulation of growth, macromolecule synthesis and differentiation, modulation of immune response, interference with oxygen activation and miscellaneous. Moreover, an overview of beneficial and adverse interactions of these antioxidants with exogenous noxae is given. Beneficial interactions include radioprotection, protection against acute toxicity of chemicals, antimutagenic activity and antitumorigenic action. Possible mechanisms of the antitumorige…
Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma
2003
Background: Inhaled corticosteroids (ICS) affect many inflammatory pathways in asthma but have little impact on cysteinyl leukotrienes. This may partly explain persistent airway inflammation during chronic ICS treatment and failure to achieve adequate asthma control in some patients. This double blind, randomised, parallel group, non-inferiority, multicentre 16 week study compared the clinical benefits of adding montelukast to budesonide with doubling the budesonide dose in adults with asthma. Methods: After a 1 month single blind run in period, patients inadequately controlled on inhaled budesonide (800 µg/day) were randomised to receive montelukast 10 mg + inhaled budesonide 800 µg/day (n…
Efficacy of leukotriene receptor antagonist in chronic urticaria. A double-blind, placebo-controlled comparison of treatment with montelukast and cet…
2001
Background The cause and pathogenesis of chronic urticaria are still poorly understood. IgE-independent reactions, are common in adult patients with chronic urticaria, who have daily spontaneous occurrence of weals. H1-receptor antagonists (antihistamines) are the major class of therapeutic agents used in the management of urticaria and angioedema. Nevertheless, chronic urticaria is often difficult to treat and may not be controlled by antihistamines alone. It has been postulated that mediators other than histamine, such as kinins, prostaglandin and leukotrienes, may be responsible for some of the symptoms in urticaria which are not controlled by antihistamines. In this study, which was ran…
Randomized placebo-controlled trial comparing desloratadine and montelukast in monotherapy and desloratadine plus montelukast in combined therapy for…
2004
BACKGROUND: H 1 -receptor antagonists are considered to be particularly effective in reducing pruritus, and they are therefore recommended as first-line treatment in patients with chronic idiopathic urticaria (CIU). Recently, antileukotriene receptors have been used in patients with CIU, either administered as monotherapy or combined with H 1 -receptor antagonists. OBJECTIVE: We compared the clinical efficacy of 5 mg of desloratadine administered once daily either as monotherapy or combined with a leukotriene antagonist, 10 mg of montelukast daily, and 10 mg of montelukast administered daily as monotherapy for the treatment of patients affected by CIU with placebo. METHODS: One hundred sixt…